Himalaya Nutravedics India IPO: Rs 26.50 Cr Issue Opens Sept 22

Himalaya Nutravedics India is launching an initial public offering to raise Rs 26.50 crore through the issuance of equity shares. The offering gives investors a chance to buy into a business operating in the Ayurvedic and Nutraceutical formulations sector.

Offering Details and Timeline

The upcoming share sale brings specific structural metrics for market participants to evaluate before placing bids. The issuance timeline and pricing parameters are structured as follows:

• Total issue size: 24,99,600 shares
• Price band: Rs 100-106 per equity share
• Subscription open date: September 22, 2026
• Subscription close date: September 24, 2026
• Listing platform: SME Platform of BSE
• Face value: Rs 10 per share

The shares are priced 10.00 times of their face value on the lower side and 10.60 times on the higher side. Nirbhay Capital Services acts as the book running lead manager to the issue, while Pooja Biyani serves as the compliance officer.

Business Operations and Model

The company handles manufacturing, marketing, and distribution of Ayurvedic and Nutraceutical formulations in India alongside third-party contract manufacturing. Its portfolio includes classical Shastric Ayurvedic formulations based on texts like Charaka Samhita, Sushruta Samhita, Ashtanga Hridaya, and Bhaishajya Ratnavali. It also produces proprietary Ayurvedic formulations and nutraceutical products across multiple dosage forms including soft gelatin capsules, hard gelatin capsules, tablets, liquid orals, and medicated oils.

A hybrid business model balances its own formulations with third-party manufacturing operations. The own-brand segment covers classical Ayurvedic formulations, proprietary Ayurvedic formulations, and nutraceutical supplements. Operations span a pan-India presence supported by a stockiest-driven distribution network and an on-ground sales team comprising approximately 56 personnel, including regional managers and medical representatives. Marketing follows a doctor-centric, offline model focused on scientific detailing, continuing medical education programs, medical camps, and relationship-based engagement rather than mass-media advertising.

Use of Proceeds

Net proceeds generated from the public offering will be deployed across specific corporate objectives. The capital allocation plan includes the following key areas:

• Funding working capital requirements
• Investing in branding, digital marketing, and sales expansion
• General corporate purposes